Overview
- Hims & Hers, in a Thursday integration with Eli Lilly’s LillyDirect, enabled providers to route prescriptions for Zepbound vials, the KwikPen injector, and Foundayo for branded fulfillment.
- The company’s stock rose about 7% after the announcement as investors reacted to broader access to FDA‑approved GLP‑1 drugs.
- The Lilly arrangement follows a March settlement with Novo Nordisk that added Wegovy access and led Hims to scale back large‑scale compounding of GLP‑1s.
- Leerink Partners analyst Michael Cherny questioned whether Hims offers more than a front door to branded products sold by drugmakers.
- J.P. Morgan on Friday initiated coverage at Overweight with a $35 target, pointing to branded access and a growth path built on subscription care and fulfillment partnerships.